It is argued that recent improvements in overall survival (OS) were mostly due to advances in the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (ABC) [7, 8]. The gene discussed is ERBB2; the disease is breast carcinoma.